Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study

The R2 (lenalidomide-rituximab) and R2 with bendamustine (R2B) regimens are both feasible in relapsed/refractory follicular lymphoma (R/R FL), but prospective phase II data on R2B are lacking. In this multinational, prospective, randomised, non-comparative trial, patients with R/R FL were randomise...

Description complète

Détails bibliographiques

Auteurs principaux:	Marie José Kersten, Martin Dreyling, Kim M. Linton, Dana Chitu, Gerben J.C. Zwezerijnen, Sanne H. Tonino, Marcel Kap, Roberto Liu, Christel van Hooije, Martine E.D. Chamuleau, Hein P.J. Visser, Eva de Jongh, Erik A.F. Marijt, Maria B.L. Leys, Yavuz M. Bilgin, Jan Dürig, Pamela McKay, Tjeerd Snijders, Andrew Pettitt, Monique C. Minnema, Gabriele Prange-Krex, Marloes L.H. Cuijpers, Lara H. Bohmer, Lidwine W. Tick, Axel Florschutz, Matthijs Silbermann, Rob Fijnheer, Aart Beeker, Nelleke Tolboom, Cristina Mitea, Anne I.J. Arens, Sanne E. Wiegers, Martijn W. Heymans, Wolfram Klapper, Sarah E. Coupland, Daphne de Jong, Jeanette K. Doorduijn, Josée M. Zijlstra
Format:	Artigo
Langue:	Inglês
Publié:	Ferrata Storti Foundation 2026-04-01
Collection:	Haematologica
Accès en ligne:	https://haematologica.org/article/view/14120
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!